文献速递泌尿生殖与妇科肿瘤放疗

局部晚期前列腺癌雄激素剥夺治疗时长:NRG肿瘤学RTOG 9202长期更新

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-02-12

RTOG 9202是一项3期随机试验,纳入1554例局部晚期非转移性前列腺癌患者,比较短期ADT(4个月)联合根治性放疗与长期ADT(上述方案加24个月戈舍瑞林)联合放疗。中位随访19.6年,长期ADT显著改善无病生存、局部进展、远处转移、疾病特异性生存和总生存,应视为标准治疗。

要点

  • 长期ADT显著降低局部进展(46%)和远处转移(36%)风险。
  • 长期ADT改善疾病特异性生存(30%)和总生存(12%),非前列腺癌死亡率无差异。

核心结论

  • 长期ADT联合放疗优于短期ADT联合放疗,应视为局部晚期非转移性前列腺癌的标准治疗。

研究设计与样本

  • 3期随机试验纳入1554例cT2c-T4、N0-Nx、PSA<150 ng/mL且无远处转移的前列腺癌患者,随机接受短期ADT(4个月氟他胺+戈舍瑞林)联合放疗或长期ADT(短期方案+额外24个月戈舍瑞林)联合放疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Trial RTOG 9202 was a phase 3 randomized trial designed to determine the optimal duration of androgen deprivation therapy (ADT) when combined with definitive radiation therapy (RT) in the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate. Long-term follow-up results of this study now available are relevant to the management of this disease. METHODS AND MATERIALS: Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin). RESULTS: Among 1520 protocol-eligible and evaluable patients, the median follow-up time for this analysis was 19.6 years. In analysis adjusted for prognostic covariates, LTAD improved disease-free survival (29% relative reduction in failure rate, P<.0001), local progression (46% relative reduction, P=.02), distant metastases (36% relative reduction, P<.0001), disease-specific survival (30% relative reduction, P=.003), and overall survival (12% relative reduction, P=.03). Other-cause mortality (non-prostate cancer) did not differ (5% relative reduction, P=.48). CONCLUSIONS: LTAD and RT is superior to STAD and RT for the treatment of locally advanced nonmetastatic adenocarcinoma of the prostate and should be considered the standard of care.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lawton CAF, Lin X, Hanks GE, et al. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017. PMID: 28463149. doi:10.1016/j.ijrobp.2017.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。